Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)
Close on Nov 17, 2026Market cap $53.58MP/E –Yield –
Heron Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Heron Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -7.2%. For fiscal 2025 it was -1.6%, against -8.0% the year before. The highest annual figure on record is -1.6% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1.6% | +6.4 |
| FY2024 | Dec 31, 2024 | -8.0% | +79.1 |
| FY2023 | Dec 31, 2023 | -87.1% | +75.1 |
| FY2022 | Dec 31, 2022 | -162.2% | +90.1 |
| FY2021 | Dec 31, 2021 | -252.3% | +5.1 |
| FY2020 | Dec 31, 2020 | -257.4% | −113.1 |
| FY2019 | Dec 31, 2019 | -144.3% | +93.1 |
| FY2018 | Dec 31, 2018 | -237.4% | +394.9 |
| FY2017 | Dec 31, 2017 | -632.4% | +12730.8 |
| FY2016 | Dec 31, 2016 | -13363.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -5.4% | −1.0 |
| Q1 FY2026 | Mar 31, 2026 | -13.7% | −21.8 |
| Q4 FY2025 | Dec 31, 2025 | 0.1% | −10.1 |
| Q3 FY2025 | Sep 30, 2025 | -10.7% | +2.9 |
| Q2 FY2025 | Jun 30, 2025 | -4.4% | +13.5 |
| Q1 FY2025 | Mar 31, 2025 | 8.1% | +21.9 |
| Q4 FY2024 | Dec 31, 2024 | 10.2% | +40.1 |
| Q3 FY2024 | Sep 30, 2024 | -13.6% | +65.7 |
| Q2 FY2024 | Jun 30, 2024 | -17.9% | +115.6 |
| Q1 FY2024 | Mar 31, 2024 | -13.8% | +97.8 |
| Q4 FY2023 | Dec 31, 2023 | -29.9% | +37.9 |
| Q3 FY2023 | Sep 30, 2023 | -79.3% | +78.4 |
| Q2 FY2023 | Jun 30, 2023 | -133.5% | +45.6 |
| Q1 FY2023 | Mar 31, 2023 | -111.6% | +156.6 |
| Q4 FY2022 | Dec 31, 2022 | -67.8% | +191.4 |
| Q3 FY2022 | Sep 30, 2022 | -157.7% | +64.9 |
| Q2 FY2022 | Jun 30, 2022 | -179.1% | +90.3 |
| Q1 FY2022 | Mar 31, 2022 | -268.2% | −7.9 |
| Q4 FY2021 | Dec 31, 2021 | -259.2% | +38.3 |
| Q3 FY2021 | Sep 30, 2021 | -222.6% | +69.8 |
| Q2 FY2021 | Jun 30, 2021 | -269.4% | −23.5 |
| Q1 FY2021 | Mar 31, 2021 | -260.3% | −52.7 |
| Q4 FY2020 | Dec 31, 2020 | -297.5% | −128.3 |
| Q3 FY2020 | Sep 30, 2020 | -292.4% | −210.7 |
| Q2 FY2020 | Jun 30, 2020 | -245.9% | −104.7 |
| Q1 FY2020 | Mar 31, 2020 | -207.6% | −2.9 |
| Q4 FY2019 | Dec 31, 2019 | -169.2% | +8.7 |
| Q3 FY2019 | Sep 30, 2019 | -81.8% | +129.4 |
| Q2 FY2019 | Jun 30, 2019 | -141.2% | +83.6 |
| Q1 FY2019 | Mar 31, 2019 | -204.7% | +244.7 |
| Q4 FY2018 | Dec 31, 2018 | -177.9% | +437.7 |
| Q3 FY2018 | Sep 30, 2018 | -211.2% | +270.8 |
| Q2 FY2018 | Jun 30, 2018 | -224.9% | +269.3 |
| Q1 FY2018 | Mar 31, 2018 | -449.5% | +907.9 |
| Q4 FY2017 | Dec 31, 2017 | -615.6% | +3043.7 |
| Q3 FY2017 | Sep 30, 2017 | -482.0% | – |
| Q2 FY2017 | Jun 30, 2017 | -494.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -1357.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -3659.3% | – |
See a number that looks wrong?